Kolben, Thomas
Mannewitz, Mareike
Perleberg, Carolin
Schnell, Konstantin
Anz, David
Hahn, Laura
Meister, Sarah
Schmoeckel, Elisa
Burges, Alexander
Czogalla, Bastian
Hester, Anna
Mahner, Sven
Kessler, Mirjana
Jeschke, Udo
Corradini, Stefanie
Trillsch, Fabian
Beyer, Susanne
Funding for this research was provided by:
Universitätsklinik München
Article History
Accepted: 17 August 2022
First Online: 13 September 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The study was approved by the ethics committee of the Ludwig-Maximilians-University Munich (reference number: 048–08; 2008). Patient data were anonymized.
: Not applicable as all data are anonymized.
: Not applicable as all data are anonymized.
: T. Kolben has a relative employed at Roche and holds stock of Roche. F. Trillsch declares Research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Medac, PharmaMar, Roche, Tesaro. S. Mahner has received Research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Medac, MSD, Novartis, Olympus, PharmaMar, Roche, Sensor Kinesis, Teva, Tesaro. All other authors declare that they have no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.